Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BuFlu versus BuCy2 conditioning before allogeneic HSCT for acute myeloid leukemia
ACTRN12609000997257Phase 3Recruiting
- Sponsor
- GITMO (Gruppo Italiano Trapianto Midollo Osseo)
- Start
- Jan 2008
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of busulfan, fludarabine and cyclophosphamide in acute myeloid leukemia (AML) (2 arms), sponsored by GITMO (Gruppo Italiano Trapianto Midollo Osseo). Primary endpoint: Transplant related mortality. Started Jan 2008; status: recruiting.
02
Drugs
busulfanfludarabinecyclophosphamide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12609000997257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000997257.